Rivaroxaban reduces stroke in Afib

In a news release from the AHA, the ROCKET trial randomized patients with non-valvular Afib to warfarin or rivaroxaban (oral Xa inhibitor). The rate of stroke/emboli was significantly lower in the rivaroxaban group (1.7 vs 2.2 per 100 patient years), with no difference in rates of major bleeding. Rivaroxaban (an oral Xa inhibitor) and Dabigatran (an oral thrombin inhibitor) have both been proven to be at least as effective and safe as warfarin in reducing afib-related stroke (AHA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment